OOIR: Observatory of International Research

Papers

(The H4-Index of Critical Reviews in Oncology Hematology is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives	233
Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence	149
ctDNA as a cancer biomarker: A broad overview	121
Lung cancer in never smokers: The role of different risk factors other than tobacco smoking	111
TMB or not TMB as a biomarker: That is the question	111
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma	86
Gynecologic cancers and non-coding RNAs: Epigenetic regulators with emerging roles	81
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)	73
Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives	72
Ferroptosis: An emerging approach for targeting cancer stem cells and drug resistance	68
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study	67
International liquid biopsy standardization alliance white paper	66
Chronic inflammation towards cancer incidence: A systematic review and meta-analysis of epidemiological studies	59
Can mHealth interventions improve quality of life of cancer patients? A systematic review and meta-analysis	59
Breast cancer, screening and diagnostic tools: All you need to know	55
CD47: the next checkpoint target for cancer immunotherapy	51
Unmet supportive care needs of people with advanced cancer and their caregivers: A systematic scoping review	50
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials	49
Liquid biopsy in bladder cancer: State of the art and future perspectives	49
Emerging role of exosomes as biomarkers in cancer treatment and diagnosis	48
The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion	47
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis	46
Immunotherapy for head and neck cancer: Present and future	45
Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic review	45
Autophagy-related MicroRNAs in chronic lung diseases and lung cancer	44

The role of epithelial-mesenchymal transition in regulating radioresistance	43
Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies	42
Major and minor salivary gland tumours	42
New advances in exosome-based targeted drug delivery systems	42
Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis	41
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC	41
Comprehensive review of chromophobe renal cell carcinoma	40
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies	40
Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment	40
Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways	39
Fathoming the link between anthropogenic chemical contamination and thyroid cancer	39
COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature	39
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer	37
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?	37
Melanoma of unknown primary: New perspectives for an old story	37
A BRAF new world	37